Outcomes in COVID-19 asapiprant studies

0 0.5 1 1.5+ All studies -63% 1 194 Improvement, Studies, Patients Relative Risk Mortality -63% 1 194 ICU admission -32% 1 194 RCTs -63% 1 194 Late -63% 1 194 Asapiprant for COVID-19 c19early.org November 2025 Favorsasapiprant Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wilkerson (DB RCT) -63% 1.63 [0.78-3.42] death 16/96 10/98 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Late treatment -63% 1.63 [0.78-3.42] 16/96 10/98 63% higher risk All studies -63% 1.63 [0.78-3.42] 16/96 10/98 63% higher risk 1 asapiprant COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Effect extraction pre-specified(most serious outcome) Favors asapiprant Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wilkerson (DB RCT) -63% 1.63 [0.78-3.42] 16/96 10/98 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Late treatment -63% 1.63 [0.78-3.42] 16/96 10/98 63% higher risk All studies -63% 1.63 [0.78-3.42] 16/96 10/98 63% higher risk 1 asapiprant COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Favors asapiprant Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wilkerson (DB RCT) -32% 1.32 [0.75-2.33] 22/96 17/98 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Late treatment -32% 1.32 [0.75-2.33] 22/96 17/98 32% higher risk All studies -32% 1.32 [0.75-2.33] 22/96 17/98 32% higher risk 1 asapiprant COVID-19 ICU result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Favors asapiprant Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wilkerson (DB RCT) -63% 1.63 [0.78-3.42] death 16/96 10/98 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Late treatment -63% 1.63 [0.78-3.42] 16/96 10/98 63% higher risk All studies -63% 1.63 [0.78-3.42] 16/96 10/98 63% higher risk 1 asapiprant COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Effect extraction pre-specified(most serious outcome) Favors asapiprant Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wilkerson (DB RCT) -63% 1.63 [0.78-3.42] death 16/96 10/98 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Late treatment -63% 1.63 [0.78-3.42] 16/96 10/98 63% higher risk All studies -63% 1.63 [0.78-3.42] 16/96 10/98 63% higher risk 1 asapiprant COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Effect extraction pre-specified(most serious outcome) Favors asapiprant Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wilkerson (DB RCT) -63% 1.63 [0.78-3.42] 16/96 10/98 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Late treatment -63% 1.63 [0.78-3.42] 16/96 10/98 63% higher risk All studies -63% 1.63 [0.78-3.42] 16/96 10/98 63% higher risk 1 asapiprant COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Favors asapiprant Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wilkerson (DB RCT) -63% 1.63 [0.78-3.42] death 16/96 10/98 Improvement, RR [CI] Treatment Control Wilkerson (DB RCT) -32% 1.32 [0.75-2.33] ICU 22/96 17/98 Wilkerson (DB RCT) -24% 1.24 [0.82-1.87] severe case 34/96 28/98 Wilkerson (DB RCT) -33% 1.33 [0.89-2.00] no improv. 96 (n) 98 (n) Wilkerson (DB RCT) -23% 1.23 [0.79-1.91] progression 31/94 26/97 Asapiprant COVID-19 outcomes c19early.org November 2025 Favors asapiprant Favors control